Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18458054rdf:typepubmed:Citationlld:pubmed
pubmed-article:18458054lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C0024432lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C1456820lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C1414691lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C0205263lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:18458054lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:18458054pubmed:issue2lld:pubmed
pubmed-article:18458054pubmed:dateCreated2008-7-23lld:pubmed
pubmed-article:18458054pubmed:abstractTextDevelopment of immunomodulatory agents that enhance innate immune responses represents a promising strategy for combating infectious diseases. In the present studies, we screened a series of 71 arylcarboxylic acid hydrazide derivatives for their ability to induce macrophage tumor necrosis factor alpha (TNF-alpha) production and identified six such compounds, including one compound previously shown to be a formyl peptide receptor (FPR/FPRL1) agonist. The two most potent compounds [compound 1, nicotinic acid [5-(3-bromophenyl)-2-furyl]methylene-hydrazide; compound 2, 4-fluoro-benzoic acid [5-(3-trifluoromethyl-phenyl)-2-furyl]-methylene-hydrazide] were selected for further analysis. These compounds induced de novo production of TNF-alpha in a dose- and time-dependent manner in human and murine monocyte/macrophage cell lines and in primary macrophages. These compounds also induced mobilization of intracellular Ca(2+), production of reactive oxygen species, and chemotaxis in human and murine phagocytes. Induction of macrophage TNF-alpha production was pertussis toxin-sensitive, and analysis of the cellular target of these compounds showed that they were FPRL1-specific agonists and that this response was blocked by FPR/FPRL1 and FPRL1-specific antagonists. In addition, pharmacophore modeling showed a high degree of similarity for low-energy conformations of these two compounds to the current pharmacophore model for FPR ligands ( Mol Pharmacol 68: 1301-1310, 2005 ). Overall, these compounds represent novel FPRL1 agonists that induce TNF-alpha, a response distinct from those induced by other known FPR and FPRL1 agonists.lld:pubmed
pubmed-article:18458054pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:languageenglld:pubmed
pubmed-article:18458054pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:citationSubsetIMlld:pubmed
pubmed-article:18458054pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18458054pubmed:statusMEDLINElld:pubmed
pubmed-article:18458054pubmed:monthAuglld:pubmed
pubmed-article:18458054pubmed:issn1521-0111lld:pubmed
pubmed-article:18458054pubmed:authorpubmed-author:QuinnMark TMTlld:pubmed
pubmed-article:18458054pubmed:authorpubmed-author:TianJunJlld:pubmed
pubmed-article:18458054pubmed:authorpubmed-author:YeRichard DRDlld:pubmed
pubmed-article:18458054pubmed:authorpubmed-author:SchepetkinIgo...lld:pubmed
pubmed-article:18458054pubmed:authorpubmed-author:KhlebnikovAnd...lld:pubmed
pubmed-article:18458054pubmed:authorpubmed-author:KirpotinaLili...lld:pubmed
pubmed-article:18458054pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18458054pubmed:volume74lld:pubmed
pubmed-article:18458054pubmed:ownerNLMlld:pubmed
pubmed-article:18458054pubmed:authorsCompleteYlld:pubmed
pubmed-article:18458054pubmed:pagination392-402lld:pubmed
pubmed-article:18458054pubmed:dateRevised2011-1-7lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:meshHeadingpubmed-meshheading:18458054...lld:pubmed
pubmed-article:18458054pubmed:year2008lld:pubmed
pubmed-article:18458054pubmed:articleTitleIdentification of novel formyl peptide receptor-like 1 agonists that induce macrophage tumor necrosis factor alpha production.lld:pubmed
pubmed-article:18458054pubmed:affiliationVeterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA.lld:pubmed
pubmed-article:18458054pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18458054pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:18458054pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:18458054pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18458054pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18458054lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18458054lld:pubmed